abbvie stock forecast 2030

Morningstar: 2019 Morningstar, Inc. All Rights Reserved. Pharmaceuticals are often valued based on a philosophy of "jam tomorrow" as opposed to jam today i.e. AbbVie projected sales - immunology (my forecasts and assumptions). AbbVie income statement forecast (My table and assumptions). Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. Real-time analyst ratings, insider transactions, earnings data, and more. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX). AbbVie's stock was trading at $161.61 on January 1st, 2023. The most recent increase was . Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. writing - trading down slightly from its all-time high of >$160 achieved in early December last year. Sign in to your free account to enjoy all that MarketBeat has to offer. It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. Please. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. The important point here is that physicians will not necessarily be under any pressure to switch patients from Humira to a biosimilar, given, as Gonzalez puts it: there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. According to CEO Gonzalez: Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. Although investing in AbbVie isn't riskless, it is advisable based on what we know about the company. Export data to Excel for your own analysis. AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. And never invest or trade money you cannot afford to lose. Date. Net earnings also saw a steep rise to $4.49bn from $3.55bn, while net revenue jumped to $13.54bn from 13.01bn. Although the company has admitted that 2023 earnings will likely be down in 2022 - guidance for last year is for earnings per share ("EPS') of $13.84 - $13.88 on an adjusted diluted basis, versus $12.7 in 2021 - Gonzalez and his team were making some bold promises to investors at this year's JP Morgan Healthcare conference. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each. AbbVie's Dividend and Valuation. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. (my table and forecasts). As a result I have dropped Imbruvica revenues to just over $3.5bn in 2022 and modelled for a CAGR growth of just 1.5% between then and 2030. (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . This suggests a possible upside of 3.2% from the stock's current price. I have no business relationship with any company whose stock is mentioned in this article. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. These are Immunology, Oncology, Neurology, Virology and Eye Care. . There are currently 9 hold ratings and 7 buy ratings for the stock. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Only you can design whether Abbvie stock is the right investment for you. To date, the company had invested more than $50 billion into research through more than 250 partnerships. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. This year is off to a strong start. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. Finally, AbbVie was able to raise its financial . As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. Compare Top Brokerages Here. Stock Price Forecast The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. I am not receiving compensation for it (other than from Seeking Alpha). AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. Having so much debt in a prevailing inflationary environment is also unattractive. The company projects the U.S. toxin market (where Botox is the top product) will decline by mid-single digits. on the strength of its future rather than present portfolio. The company issued revenue guidance of -. This means that . The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. Disclosure: I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. This would represent an increase of 1.78%. Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. Any company is likely to struggle if sales of its best-selling asset begin to decline by ~20% per annum, which is traditionally the rate at which patent expired drugs' sales slip, but when the drug in question accounts for >35% of a company's sales, as Humira does, the situation becomes even more serious. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. In my last note on AbbVie (NYSE:ABBV) for Seeking Alpha - in early July - I reviewed the Big Pharma's Q1'22 earnings and looked ahead to the release of Q2'22 figures. I wrote this article myself, and it expresses my own opinions. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. ABBV closed at $152.49 on 29 June, which was above its 200-day moving average (MA) of 136.42, indicating a bullish signal for the stocks price movement ahead, according to data from TradingView. Trading CFDs is high risk and is not suitable for everyone. Psoriatic arthritis is also adding significantly to Skyrizi's momentum, where we are now approved in 54 countries. AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. During the same quarter in the prior year, the firm posted $3.31 EPS. We continue to anticipate a clearer path to strong sales growth in 2025 with high-single-digit compounded annual growth rate to the end of this decade. What is a Good Dividend Yield? To summarize, Humira may be going off-patent, but is more than capable of delivering double-digit billion revenues for another 3-4 years, and even in 2030, it could be amongst the top 20 best-selling drugs worldwide. AbbVie product revenues by quarter and year since FY20. The company employs 50,000 workers across the globe. AbbVie is led by CEO and Chairman Rick Gonzalez - likely the only Pharma CEO who lacks a college degree - who has successfully defended Humira from generic drug competition by adopting a controversial strategy of continually applying for new patents related to minor changes in manufacturing methods or administration, often referred to as a "patent thicket". Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. Please. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The company has a robust pipeline of new products that are in some stage of clinical trials. Our daily ratings and market update email newsletter. On 14 January 2022, the FDA approved Abbvies arthritis treatment drug, Rinvoq (upadacitinib), for the treatment of adults with moderately to severely active ulcerative colitis. I have no business relationship with any company whose stock is mentioned in this article. Kateryna Onyshchuk/iStock via Getty Images. Please log in to your account or sign up in order to add this asset to your watchlist. (AbbVie JPM Healthcare conference presentation). Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . psoriatic arthritis at a lower dose, again with a comparable safety profile, and has also won approval in a field where Humira has not, namely Atopic Dermatitis. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. ABBV currently yields 4.1% and has raised its dividend every year since 2013. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. (844) 978-6257. With a 5-year investment, the revenue is expected to be around +88.28%. Nevertheless, after applying the discount factor, I calculate a share price target of $151 based on DCF analysis and a slightly higher figure of $168 based on EBITDA analysis. All generate blockbuster <$1bn per annum sales - in Stelara's case >$9bn per annum, and in Enbrel's case, >$4.5bn. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Discovery Company. I am not receiving compensation for it (other than from Seeking Alpha). As we look beyond 2025, we expect combined sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira, which was more than $21 billion. 2022 Cable News Network. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. The other major plus is probably the performance of the neuroscience divisions, where as we can see, Botox (indicated for migraine treatment), atypical antipsychotic Vraylar, migraine therapy Ubrelvy and newly launched Qulipta, an oral CGRP inhibitor indicated for chronic migraine all delivered good sales growth. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. On the negative side of things, we can see that AbbVie is no longer breaking out sales within its Women's Health division, with revenues lumped into the "all other section, presumably. AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. The company reported its first revenue for Botox competitor Daxxify. As we can see the immunology division consists of only 3 assets yet by my calculation, will likely account for 50% of AbbVie's revenues in 2022 (to calculate 2022 sales revenues by product, since we do not yet have final figures, I have used 9m 2022 figures and assumed Q4 revenues will be the average of the previous 3 quarters). There is an element of risk to that as clinical trial failures are common, even for a giant like AbbVie, and even CEO Gonzalez may be forced to backtrack on some of his blockbuster sales projections. Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.12. Shares of ABBV stock can be purchased through any online brokerage account. Please disable your ad-blocker and refresh. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. It now expects full-year profit in the range of $13.92-$14.12 a share. That same month, the FDA extended the review period for Skyrizi (risankizumab), a treatment drug for moderate to severe Crohns disease in patients aged 16 and older. The Abbvie stock forecast for 2025 had the price at $259.018. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. This has been in spite of a string of macroeconomic headwinds such as the ongoing Russia-Ukraine war that has contributed to record high inflation in the US and the UK, and the companys psoriatic arthritis drug Adalimumab, known as Humira, facing biosimilar rivals in the US from 2023. GSK Free Cash Flow Forecast for 2023 - 2025 - 2030. AbbVie Inc. is a US-based biopharma company with global operations. AbbVie Stock Forecast 03-06-2023. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. AbbVie updated its FY 2024 earnings guidance on Friday, February, 10th. I also considered the long-term outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. See AbbVie Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. However, there are some general principles that can be followed in order to improve the accuracy of stock price predictions. To see all exchange delays and terms of use please see Barchart's disclaimer. Year-to-date, the stock was up slightly more than 12% while benchmark global indices have all fallen sharply amid surging inflation, interest rate hikes and slowdown worries. You should consider whether you understand how CFDs work and can afford the risks. The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. AbbVie made the bold decision to take on a heavy debt load and bid for Allergan, with the deal being completed in 2020. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Within the oncology division sales of Imbruvica fell 17% year-on-year. (my tables and forecasting). There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. AbbVie is a leading dividend payer. The analysts 12-month consensus ABBV stock price target was $159.75. AbbVie saw a increase in short interest in February. That reflects uncertainty about what the future holds for AbbVie. If you have an ad-blocker enabled you may be blocked from proceeding. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. If you have an ad-blocker enabled you may be blocked from proceeding. AbbVie has 5 focus areas for its research and products. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. ABBV-916 is therefore a real opportunity for AbbVie to develop a more effective and safer drug in the same class and claim a sizeable share of a 6m patient market. All rights reserved. The median. The company didn't offer a . Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. What is the dividend yield for AbbVie? Rinvoq's progress has been a little more circumspect, but almost as impressive. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. Note that analysts ABBV stock forecasts can be wrong. View our ABBV earnings forecast. And it couldnt be more wrong! With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! Is this happening to you frequently? I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. In general, it is important to pay attention to trends, both in the overall market and in the specific sector that a company is in. Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. The total revenue in 2021 was $56.20 billion with a 31% operating margin. Since then, however, the stock price has fallen 18% to its current price of $142.6. Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030. Price target. The material provided on this website is for information purposes only and should not be understood as an investment advice. On average, analysts rate AbbVie stock as a buy. AbbVie has a PEG Ratio of 3.51. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. I have been maintaining a revenue forecasting table for AbbVie's products which I have amended based on Q2'22 and H1'22 results, and the slightly downgraded guidance issued for 2022 - management now expects adjusted earnings per share ("EPS") of $13.78 - $13.98, representing growth of 17% at the midpoint. The "King Of Quants" sees 10X potential Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. (ABBV) AbbVie Stock Predictions from the Leading Provider of Short and Long Term Stock Price Forecasts. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". And with a dividend yield of 4.9%, AbbVie is quite attractive for investors yearning for . I have no business relationship with any company whose stock is mentioned in this article. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. As such I have downgraded my own growth expectations in the forecasting table above, reducing annual growth from 7.5%, to just 2.5%, after forecasting for $5bn revenues in FY22 - down 7.5% year-on-year. Most stock quote data provided by BATS. CNN Sans & 2016 Cable News Network. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%. A AbbVie Inc. (NYSE:ABBV) insider lowered their holding by 87% earlier this year, These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio, AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says, AbbVie (NYSE:ABBV) Receives New Coverage from Analysts at Guggenheim, AbbVie to Present at the Cowen 43rd Annual Health Care Conference, AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults with Moderate to Severe Crohn's Disease, AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO), 3 Stocks to Buy Right Now That Are Cash Cows, The painfully high price of Humira is patently wrong, AbbVie Inc. (NYSE:ABBV) SVP Sells $4,310,832.64 in Stock, StockNews.com Upgrades AbbVie (NYSE:ABBV) to "Strong-Buy", AbbVie Inc. (NYSE:ABBV) Director Sells $1,505,000.00 in Stock, Azita Saleki-Gerhardt Sells 25,000 Shares of AbbVie Inc. (NYSE:ABBV) Stock, AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need, view top-rated stocks among Wall Street analysts, 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. What is Richard A. Gonzalez's approval rating as AbbVie's CEO? AbbVie has been increasing its dividend for 51 years. The official website for the company is www.abbvie.com. The dividend payout ratio is 89.56%. It is important to do your own research, and remember that your decision to trade depends on your attitude to risk, your expertise in the market, the spread of your investment portfolio and how comfortable you feel about losing money. Enjoy your holiday weekend and catch up on our most read stories this week. You should do your own research and never invest money you cannot afford to lose. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. AbbVie CEO Gonzalez told the audience at the JPM Healthcare conference that: We now have a little over 90% access for next year for Humira at parity. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. We expect that to happen in 2027 with continued significant growth anticipated in the following years. 326 E 8th St #105, Sioux Falls, SD 57103 The risks associated with aesthetics are that the industry can be severely buffeted by economic headwinds, as these products are more consumer focused and are often considered an unnecessary expenditure in times of hardship. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. Over the years, AbbView Inc. has made numerous acquisitions. That was below AbbVie stock analysts' view for $14.16. The above table shows quarterly and annual product revenues going back to FY20, whilst the last 4 columns show revenue growth percentage between FY20 and FY21, then revenue growth between Q2'21 and Q2'22, the sequential (quarter on quarter) growth, followed by product sales as a percentage of revenues. AbbVie has said it expects to generate high-single-digit CAGR growth from 2025 to the end of the decade after revenues fall in 2023 due to Humira LOE. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. AbbVie stock is one of the most well-known pharmaceutical companies. Investors needn't panic however - Humira's replacements are expected by AbbVie's CEO to generate even higher revenues per annum. I have no business relationship with any company whose stock is mentioned in this article. I'll also share some a forward income statement and discounted cash flow analysis that suggests the present value of AbbVie shares ought to trade as high as $176, implying that shares are presently discounted by as much as 18% to their true worth. What guidance has AbbVie issued on next quarter's earnings? Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience. approvals of Humira, Skyrizi, Rinvoq (AbbVie JPM Healthcare conference presentation). Since then, however, the stock price has fallen 18% to. Capital Com is an execution-only service provider. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few.